We aim to evaluate the degree of agreement between immunohistochemistry (IHC) and flow cytometry (FC) in the diagnosis of malignant hematologic diseases, mainly lymphomas. A total of 260 bone marrow biopsies, 255 bone marrow aspirates, and 5 other suspensions of 260 patients used for diagnosis of a hematologic malignancy between 2009 and 2012 with both, IHC and FC, were retrospectively analyzed. Overall there is a substantial degree of agreement (κ=0.69) between IHC and FC. Chronic lymphocytic leukemia/small lymphocytic lymphoma, mature T-cell neoplasms, acute leukemias, and myelodysplastic syndromes had the highest concurrence rates (>80%). In nonconcordant cases, an IHC provided diagnosis in 25.4%, and an FC in 4.6%. Lymphomas were diagnosed by an IHC only in 51% of the cases. Both methods have good concurrence rates and are complementary. An IHC has the advantage of combining markers, morphology, and tissue immunoarchitecture, which is beneficial in the diagnosis of lymphomas. An FC is required in leukemias as it is faster and plays an important role in minimal residual disease.

中文翻译：

---

骨髓免疫组织化学和流式细胞术在以淋巴瘤为重点的恶性血液病诊断中的应用

我们旨在评估免疫组织化学 (IHC) 和流式细胞术 (FC) 在恶性血液疾病（主要是淋巴瘤）诊断中的一致性程度。回顾性分析了 260 份骨髓活检、255 份骨髓抽吸物和 260 名患者的 5 份其他悬浮液，用于在 2009 年至 2012 年间诊断 IHC 和 FC 的血液系统恶性肿瘤。总体而言，IHC 和 FC 之间存在相当程度的一致性 (κ=0.69)。慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、成熟 T 细胞肿瘤、急性白血病和骨髓增生异常综合征的并发率最高（>80%）。在不一致的情况下，25.4% 的 IHC 和 4.6% 的 FC 提供了诊断。IHC 仅在 51% 的病例中诊断出淋巴瘤。两种方法都具有良好的并发率并且是互补的。IHC 具有结合标志物、形态学和组织免疫结构的优势，有利于淋巴瘤的诊断。白血病需要 FC，因为它更快，并且在微小残留病中起重要作用。